# GSK5784283 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/gsk5784283

> The next catalyst for GSK5784283, sponsored by GSK plc (GSK), is its topline data readout, Feb to May 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GSK5784283 |
| Codes | GSK5784283 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Pulmonary Disease, Chronic Obstructive](https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive), [Nasal Polyps](https://sec-api.dev/indications/nasal-polyps), [Asthma](https://sec-api.dev/indications/asthma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 14, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06748053 (A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06748053

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780643

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780643 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-15 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780643

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782957 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782957

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782970 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782970

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782957 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782957

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782970 (A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782970

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782996

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07782996 (A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-04 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07782996

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780656

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780669

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780656 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780656

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07780669 (A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07780669

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Ohtuvayre (ensifentrine)](https://sec-api.dev/pdufa/ensifentrine) (MRK)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/gsk5784283.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GSK5784283 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/gsk5784283

```bibtex
@misc{secapidev_pdufa_gsk5784283_20261116,
  title        = {GSK5784283 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/gsk5784283}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_gsk5784283_20261116","title":"GSK5784283 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/gsk5784283","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
